Read by QxMD icon Read

Apheresis Yield

Tomas Jelinek, Lucie Adamusova, Tereza Popkova, Ivana Tvrda, Jana Smejkalova, Michal Simicek, Dana Salounova, Michal Kascak, Jana Mihalyova, Hana Plonkova, Juraj Duras, Milan Navratil, Roman Hajek, Zdenek Koristek
Cyclophosphamide (Cy) plus granulocyte-colony stimulating factor (G-CSF) is currently a standard regimen for hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma (MM). However, cytarabine (AraC) in intermediate doses plus G-CSF seems to have a higher mobilization efficacy. The aim of this study was to retrospectively compare mobilization using AraC and Cy. Thirty consecutive MM patients were mobilized by Cy + G-CSF, and the subsequent 40 patients by AraC + G-CSF. Both groups were comparable...
November 20, 2018: Bone Marrow Transplantation
A Partanen, J Valtola, A Ropponen, H Kuitunen, O Kuittinen, K Vasala, L Ågren, K Penttilä, L Keskinen, M Pyörälä, T Nousiainen, T Selander, P Mäntymaa, J Pelkonen, V Varmavuo, E Jantunen
BACKGROUND: Data are limited on the long-acting granulocyte-colony stimulating factors (G-CSFs) pegfilgrastim (PEG) and lipegfilgrastim (LIPEG) compared with filgrastim (FIL) regarding the mobilization efficiency of CD34+ cells, graft cellular composition, and engraftment. STUDY DESIGN AND METHODS: In this prospective nonrandomized study, 36 patients with non-Hodgkin lymphoma received FIL, 67 received PEG, and 16 patients received LIPEG as a cytokine after chemotherapy...
November 19, 2018: Transfusion
Abdel-Ghani M Azzouqa, Kinda Jouni, Vivek Roy, Abba C Zubair
BACKGROUND: Mobilization regimen choice is a significant contributing factor for successful hematopoietic progenitor cell (HPC) collection by leukocytapheresis and reaching the target CD34+ cell dose. How mobilization regimen affects collection efficiency and the quality of products collected using the Spectra Optia apheresis instrument is not fully known. METHODS: We evaluated the impact of granulocyte-colony stimulating factor (GCSF) and GCSF/plerixafor mobilization regimens on CE and product composition...
November 14, 2018: Journal of Clinical Apheresis
R N Makroo, Dhaval Fadadu, Soma Agrawal, Mohit Chowdhry
The double dose plateletpheresis (DDP) is considered to be a cost effective way of preparing platelets, owing to the low incidence of infectious complications and by also minimizing allogeneic donor exposure to the patients. We aimed at collecting DDP at our center and study its effect on donor hematological parameters, evaluate the product quality and the adverse donor reactions thereafter. Double Dose Platelet was collected from 160 eligible apheresis donors on Amicus cell separator (Fenwal, Inc. Three Corporate Drive Lake Zurich, IL, USA)...
October 2018: Indian Journal of Hematology & Blood Transfusion
Axel Karow, Anna Wilhelm, Roland A Ammann, Gabriela M Baerlocher, Thomas Pabst, Behrouz Mansouri Taleghani, Jochen Roessler, Kurt Leibundgut
Collection of peripheral blood progenitor cells by leukapheresis is the preferred method to obtain grafts for autologous transplantation. Optimizing this procedure is important to warrant sufficient cell yield and reduce associated risks. To obtain sufficient to optimal yields of ≥ 2 to ≥ 5 × 106 CD34+ cells/kg body weight with a single leukapheresis procedure, success rates between 83 and 92% have been reported in children. In this retrospective study, we describe an improved protocol for autologous stem cell collection with an extraordinarily high success rate applied in 122 consecutive pediatric patients treated at the University Hospital Bern between 2004 and 2017...
October 23, 2018: Bone Marrow Transplantation
Kathelijne Cjm Kraal, Ilse Timmerman, Hannah M Kansen, Cor van den Bos, Jozsef Zsiros, Henk van den Berg, Sebastiaan F Somers, Eric Braakman, Annemarie M L Peek, Max van Noesel, C Ellen van der Schoot, Marta Fiocco, Huib N Caron, Carlijn Voermans, Godelieve A M Tytgat
PURPOSE: Targeted radiotherapy with 131 Iodine-meta-iodobenzylguanidine (131 I-MIBG) is effective for neuroblastoma (NBL), although optimal scheduling during high-risk (HR) treatment is being investigated. We aimed to evaluate the feasibility of stem cell apheresis and study hematological reconstitution after autologous stem cell transplantation (ASCT) in HR-NBL patients treated with upfront 131 I-MIBG-therapy. EXPERIMENTAL DESIGN: In two prospective multi-center cohort studies, newly diagnosed HR-NBL patients were treated with two courses of 131 I-MIBG-therapy, followed by a HR-induction protocol...
October 12, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Erica B Esrick, John P Manis, Heather Daley, Cristina Baricordi, Hélène Trébéden-Negre, Francis J Pierciey, Myriam Armant, Sarah Nikiforow, Matthew M Heeney, Wendy B London, Luca Biasco, Mohammed Asmal, David A Williams, Alessandra Biffi
Novel therapies for sickle cell disease (SCD) based on genetically engineered autologous hematopoietic stem and progenitor cells (HSPCs) are critically dependent on a safe and effective strategy for cell procurement. We sought to assess the safety and efficacy of plerixafor when used in transfused patients with SCD for HSC mobilization. Six adult patients with SCD were recruited to receive a single dose of plerixafor, tested at lower than standard (180 µg/kg) and standard (240 µg/kg) doses, followed by CD34+ cell monitoring in peripheral blood and apheresis collection...
October 9, 2018: Blood Advances
Kanji Miyazaki, Kenshi Suzuki
Mobilization failure is a major concern in patients undergoing hematopoietic cell transplantation, especially in an autologous setting, as almost all donor harvests can be accomplished with granulocyte-colony stimulating factor (G-CSF) alone. Poor mobilizers, defined as those with a peripheral blood CD34+ cell count ≤20 cells/μl after mobilization preceding apheresis is a significant risk factor for mobilization failure. We recommend preemptive plerixafor plus G-CSF (filgrastim, 10 μg/kg daily) as a first mobilization strategy, which yields sufficient peripheral blood progenitor cells (PBPCs) in almost all patients and avoids otherwise unnecessary remobilization...
September 11, 2018: Transfusion and Apheresis Science
Tomasz Czerw, Maria Sadus-Wojciechowska, Katarzyna Michalak, Jacek Najda, Wlodzimierz Mendrek, Malgorzata Sobczyk-Kruszelnicka, Magdalena Glowala-Kosinska, Agata Chwieduk, Iwona Mitrus, Andrzej Smagur, Jerzy Holowiecki, Sebastian Giebel
Mobilization of hematopoietic stem cells for patients with multiple myeloma (MM) may be done using either steady-state granulocyte colony-stimulating factor (G-CSF) or a combination of chemotherapy with G-CSF. The goal of this randomized, open-label, phase 3 trial was to compare the efficacy of chemomobilization using intermediate-dose cytarabine (ID-AraC) plus G-CSF with G-CSF alone in patients with MM referred for tandem autologous stem cell transplantation (autoSCT). The percentage of patients with stem cell yield of at least 5 × 106 CD34+ cells/kg was the primary endpoint...
September 26, 2018: Biology of Blood and Marrow Transplantation
Michael Erdmann, Ugur Uslu, Manuel Wiesinger, Mareke Brüning, Tobias Altmann, Erwin Strasser, Gerold Schuler, Beatrice Schuler-Thurner
Dendritic cell (DC)-based vaccines have been successfully used for immunotherapy of cancer and infections. A major obstacle is the need for high-level class A cleanroom cGMP facilities for DC generation. The CliniMACS Prodigy® (Prodigy) represents a new platform integrating all GMP-compliant manufacturing steps in a closed system for automated production of various cellular products, notably T cells, NK cells and CD34+ cells. We now systematically tested its suitability for producing human mature monocyte-derived DCs (Mo-DCs), and optimized it by directly comparing the Prodigy approach to our established standard production of Mo-DCs from elutriated monocytes in dishes or bags...
September 25, 2018: Journal of Immunological Methods
Akihiko Yokohama, Keiko Yokote, Takayuki Maruhashi
Peripheral blood stem cells (PBSCs) are currently one of the most important stem cell sources for hematopoietic stem cell transplantation as well as cell therapy for ischemic heart disease or critical limb ischemia. Thus, it is sometimes necessary to collect autologous PBSCs from donors who have comorbidities. In terms yield, a sufficient number of PBSCs can be collected from donors with comorbidities for performing cell therapy if their age is < 60 years or up to a maximum of 70 years, although the number of PBSCs collected from older donors would probably be lower than that obtained from younger donors...
September 18, 2018: Transfusion and Apheresis Science
Nicole L Watts, Marisa B Marques, Daniel B Peavey, Racquel Innis-Shelton, Ayman Saad, Stasi Ad, Donna Salzman, Lawrence S Lamb, Luciano J Costa
Filgrastim (FIL) is the most common growth factor combined with plerixafor for autologous hematopoietic progenitor cell mobilization, but requires daily, multi-injection administration. We adopted a standardized mobilization regimen with pegfilgrastim (PEG) and upfront plerixafor, allowing for a single injection given the long half-life and slow elimination of PEG. Between 2015 and 2017, a total of 235 patients with lymphoma or plasma cell dyscrasias underwent mobilization with PEG 6 mg on day 1 and upfront plerixafor 24 mg on day 3, followed by apheresis on day 4 regardless of peripheral blood CD34+ cells...
February 2019: Biology of Blood and Marrow Transplantation
Ruqayyah J Almizraq, Philip J Norris, Heather Inglis, Somaang Menocha, Mathijs R Wirtz, Nicole Juffermans, Suchitra Pandey, Philip C Spinella, Jason P Acker, Jennifer A Muszynski
Transfusion of red cell concentrates (RCCs) is associated with increased risk of adverse outcomes that may be affected by different blood manufacturing methods and the presence of extracellular vesicles (EVs). We investigated the effect of different manufacturing methods on hemolysis, residual cells, cell-derived EVs, and immunomodulatory effects on monocyte activity. Thirty-two RCC units produced using whole blood filtration (WBF), red cell filtration (RCF), apheresis-derived (AD), and whole blood-derived (WBD) methods were examined (n = 8 per method)...
September 25, 2018: Blood Advances
Maryou B Lambros, George Seed, Semini Sumanasuriya, Veronica Gil, Mateus Crespo, Mariane Fontes, Rob Chandler, Niven Mehra, Gemma Fowler, Berni Ebbs, Penny Flohr, Susana Miranda, Wei Yuan, Alan Mackay, Ana Ferreira, Rita Pereira, Claudia Bertan, Ines Figueiredo, Ruth Riisnaes, Daniel Nava Rodrigues, Adam Sharp, Jane Goodall, Gunther Boysen, Suzanne Carreira, Diletta Bianchini, Pasquale Rescigno, Zafeiris Zafeiriou, Joanne Hunt, Deirdre Moloney, Lucy Hamilton, Rui P Neves, Joost Swennenhuis, Kiki Andree, Nikolas H Stoecklein, Leon W M M Terstappen, Johann S de Bono
Purpose: Circulating tumor cells (CTCs) have clinical relevance, but their study has been limited by their low frequency. Experimental Design: We evaluated liquid biopsies by apheresis to increase CTC yield from patients suffering from metastatic prostate cancer, allow precise gene copy-number calls, and study disease heterogeneity. Results: Apheresis was well tolerated and allowed the separation of large numbers of CTCs; the average CTC yield from 7.5 mL of peripheral blood was 167 CTCs, whereas the average CTC yield per apheresis (mean volume: 59...
August 9, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Catherine Ravanat, Arnaud Dupuis, Nadine Marpaux, Christian Naegelen, Guillaume Mourey, Herve Isola, Michel Laforêt, Pascal Morel, Christian Gachet
BACKGROUND AND OBJECTIVES: Small batch-pooled (mini-pool) whole blood (WB)-derived plasma could be an alternative cost-effective source of therapeutic plasma (TP), but carries an increased risk of transfusion-transmitted infection due to exposure of the recipient to several donors. This risk can be mitigated by inactivation of pathogens susceptible to the amotosalen-UVA (AUVA)-treatment. We evaluated the conservation of coagulation factors in AUVA-plasma prepared from WB stored overnight under routine operating conditions, to determine its therapeutic efficacy...
October 2018: Vox Sanguinis
Raphael Teipel, Uta Oelschlägel, Katrin Wetzko, Maria Schmiedgen, Michael Kramer, Elke Rücker-Braun, Kristina Hölig, Malte von Bonin, Katharina Heidrich, Anke Fuchs, Rainer Ordemann, Frank Kroschinsky, Martin Bornhäuser, Gero Hütter, Helmuth Schmidt, Gerhard Ehninger, Johannes Schetelig, Falk Heidenreich
This study was conducted to characterize and compare peripheral blood stem cell grafts from healthy donors who underwent granulocyte colony-stimulating factor (G-CSF) mobilization and subsequently received 1 dose of plerixafor after insufficient stem cell yields were achieved at the first apheresis. Aliquots from 35 donors were collected from the first apheresis after mobilization with G-CSF alone and from the second apheresis after additional plerixafor administration. Samples were freshly analyzed for cellular subsets by 8-color flow cytometry...
June 21, 2018: Biology of Blood and Marrow Transplantation
Krzysztof Bartnik, Martyna Maciejewska, Roiya Farhan, Elżbieta Urbanowska, Małgorzata Król, Maria Król, Magdalena Feliksbrot, Wiesław Wiktor-Jędrzejczak, Emilian Snarski
BACKGROUND: Recently, novel protocol utilizing Continuous Mononuclear Cell Collection (cMNC) have been introduced for leukapheresis. We compared the efficacy of cMNC with an older protocol - mononuclear cell collection (MNC) for CD34+ cell collection in unrelated donors with negative stem cell collection predictors. MATERIAL AND METHODS: Retrospective data from a series of 258 consecutive unrelated hematopoietic stem cell donors was included in this single-center study (80 donors collected with cMNC and 178 with MNC)...
June 2018: Transfusion and Apheresis Science
Arne Knörck, Stefanie Marx, Kim S Friedmann, Sylvia Zöphel, Lisa Lieblang, Carmen Hässig, Isabelle Müller, Jan Pilch, Urban Sester, Markus Hoth, Hermann Eichler, Martina Sester, Eva C Schwarz
BACKGROUND: Research with primary human white blood cell (WBC) subpopulations requires high quantity, quality, and functionality of peripheral blood mononuclear cells (PBMCs) as a source to further characterize cellular subpopulations such as T and B lymphocytes, monocytes, or natural killer cells. Apart from buffy coats derived from whole blood, residual blood from preparative hemapheresis kits are used as a source for PBMCs, but knowledge on the yield and functionality of cells from different devices is limited...
June 2018: Transfusion
S Bashir, A Meli, R Cardigan
BACKGROUND AND OBJECTIVES: Two of the predictive factors of the quality of small volumes of platelets suitable for paediatric use are bag size and material. This study evaluated the storage properties of paediatric platelet aliquots in TOTM-, BTHC- or DINCH-PVC bags. METHODS/MATERIALS: (i) Three apheresis platelet concentrates (PC) were pooled and split into three units. One was retained as an adult unit (control; polyolefin bag). The second and third units were split into four MacoPharma TOTM-PVC and BTHC-PVC paediatric bags, respectively...
October 2018: Transfusion Medicine
Soumya Pandey, Michele Cottler-Fox
PURPOSE: We evaluated the Optia® continuous mononuclear collection (CMNC) system for hematopoietic progenitor cell-apheresis (HPC-A) collection (Terumo BCT, Lakewood, CO) compared to the COBE® Spectra (Terumo BCT, Lakewood, CO), including both large volume leukapheresis (LVL) and non-LVL collections. METHODS: We performed a retrospective data analysis of all autologous HPC-A collections with the Optia® CMNC system (n = 93; LVL = 59, non-LVL = 34) since implementation at our institution and compared it with a similar number of concurrent collections utilizing the COBE® Spectra (n = 96; LVL = 68, non-LVL = 28)...
August 2018: Journal of Clinical Apheresis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"